Skip to main content
Livermore
Livermore
ZHEN

Exor Capital LLP

SEC CIK
0001732768
Latest filing
Jul 29, 2026

The latest 13F from Exor Capital LLP covers Q2 2026 (filed Jul 29, 2026): 31 long positions worth $4.65B. The top 10 holdings make up 80.5% of the portfolio, and the largest is Teva Pharmaceutical Industries Ltd (TEVA) at 14.7%. Livermore has 24 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
6
Est. +$635.3M
Added
4
Est. +$190.1M
Reduced
12
Est. −$849.8M
Sold out
9
Est. −$315.0M

Top 5 holdings

Share of this quarter's portfolio value

  1. TEVATeva Pharmaceutical Industries Ltd
    14.7%$684.6MHistory
  2. CVNACarvana Co.
    13.2%$611.1MHistory
  3. MOHMolina Healthcare, Inc.
    12.4%$574.4MHistory
  4. PSKYParamount Skydance Corp
    9.8%$455.8MHistory
  5. RRCRange Resources Corp
    8.8%$410.8MHistory

Share of portfolio

Top 5 holdings and the other 26 positions, by share of portfolio value

  1. TEVA14.7%
  2. CVNA13.2%
  3. MOH12.4%
  4. PSKY9.8%
  5. RRC8.8%
  6. Other 26 positions41.1%

Biggest buys

New and added positions, by estimated amount bought

  1. MOHMolina Healthcare, Inc.
    +$574.4MNewHistory
  2. RRCRange Resources Corp
    +$143.2MAddedHistory
  3. SSMRSunshine Silver Mining & Refining Co
    +$26.4MNewHistory
  4. NBISNebius Group N.V.
    +$21.2MAddedHistory
  5. TSMTaiwan Semiconductor Manufacturing Co Ltd
    +$15.1MAddedHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. MOHMolina Healthcare, Inc.
    +12.36 pp0.0% → 12.4%History
  2. RRCRange Resources Corp
    +2.40 pp6.4% → 8.8%History
  3. TSMTaiwan Semiconductor Manufacturing Co Ltd
    +1.32 pp1.9% → 3.2%History
  4. NBISNebius Group N.V.
    +0.96 pp0.3% → 1.2%History
  5. NVDANVIDIA Corp
    +0.75 pp2.1% → 2.9%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. TEVATeva Pharmaceutical Industries Ltd
    −$256.3MReducedHistory
  2. VanEck ETF Trust92189F791
    −$238.9MSold out
  3. CVNACarvana Co.
    −$227.5MReducedConverted for a 5-for-1 splitHistory
  4. VALValaris Ltd
    −$94.0MReducedHistory
  5. AGFirst Majestic Silver Corp
    −$79.4MReducedHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. VanEck ETF Trust92189F791
    −4.74 pp4.7% → 0.0%
  2. VALValaris Ltd
    −3.44 pp7.2% → 3.8%History
  3. CVNACarvana Co.
    −2.73 pp15.9% → 13.2%History
  4. NGNovagold Resources Inc
    −2.51 pp6.6% → 4.1%History
  5. AGFirst Majestic Silver Corp
    −2.32 pp4.3% → 1.9%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$4.65B
−$396.6M (−7.9%) vs. prior quarter
Positions
31
−3 vs. prior quarter
Top 10 concentration
80.5%
Top 10 as share of value
Turnover
17.0%
Q2 2026, one quarter
Average holding period
12.2 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

22 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $5.67B (Q4 2025)

Q1 2021: $872.3MQ2 2021: $1.15BQ3 2021: $1.22BQ4 2021: $1.05BQ1 2022: $1.48BQ2 2022: $1.03BQ3 2022: $1.09BQ4 2022: $812.9MQ1 2023: $1.40BQ2 2023: $1.55BQ3 2023: $1.86BQ4 2023: $2.08BQ1 2024: $2.39BQ2 2024: $2.98BQ3 2024: $3.47BQ4 2024: $3.73BQ1 2025: $3.83BQ2 2025: $4.65BQ3 2025: $5.34BQ4 2025: $5.67BQ1 2026: $5.04BQ2 2026: $4.65B
Q1 2021Q2 2026
13F filings of Exor Capital LLP by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Jul 29, 202631$4.65BTEVACVNAMOHvs. Q1 2026SEC
Q1 2026May 14, 202634$5.04BTEVACVNAPSKYvs. Q4 2025SEC
Q4 2025Feb 10, 202638$5.67BCVNATEVAPSKYvs. Q3 2025SEC
Q3 2025Nov 13, 2025Amended34$5.34BCVNAPSKYTEVAvs. Q2 2025SEC
Q2 2025Aug 13, 202542$4.65BCVNAParamount GlobalTEVAvs. Q1 2025SEC
Q1 2025May 15, 202544$3.83BCVNAParamount GlobalTEVAvs. Q4 2024SEC
Q4 2024Feb 4, 202553$3.73BCVNATEVAParamount Globalvs. Q3 2024SEC
Q3 2024Nov 13, 202446$3.47BCVNATEVAParamount Globalvs. Q2 2024SEC
Q2 2024Aug 12, 202450$2.98BCVNATEVAParamount Globalvs. Q1 2024SEC
Q1 2024May 15, 202447$2.39BTEVACVNAVALvs. Q4 2023SEC
Q4 2023Feb 13, 202434$2.08BTEVACVNAVALvs. Q3 2023SEC
Q3 2023Nov 13, 202333$1.86BTEVARRCVALvs. Q2 2023SEC
Q2 2023Aug 11, 202333$1.55BRRCTEVASLBvs. Q1 2023SEC
Q1 2023May 15, 202320$1.40BRRCTEVAWFRDvs. Q4 2022SEC
Q4 2022Feb 15, 202318$812.9MSLBNGHMYvs. Q3 2022SEC
Q3 2022Nov 7, 202216$1.09BCCJWFRDRRCvs. Q2 2022SEC
Q2 2022Aug 12, 202216$1.03BCCJRRCWFRDvs. Q1 2022SEC
Q1 2022May 3, 202215$1.48BCCJRRCWFRDvs. Q4 2021SEC
Q4 2021Feb 14, 202318$1.05BVEONSLBNGvs. Q3 2021SEC
Q3 2021Nov 1, 202113$1.22BCCJRRCSLBvs. Q2 2021SEC
Q2 2021Jul 29, 202113$1.15BCCJSLBVEONvs. Q1 2021SEC
Q1 2021Apr 29, 20219$872.3MCCJSLBVEON–SEC

13D and 13G filings

Companies where Exor Capital LLP reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

4 companies, largest stake first.

Companies where Exor Capital LLP owns 5% or more
CompanyLatest formStakeChangeFirst filedLatest filingFiling
NGNovagold Resources Inc13G8.58%34.9M sharesNewAug 11, 20251 filingAug 11, 2025SEC
VEONVEON Ltd.13G/A7.12%131.6M shares−1.62 ppfrom 8.74%Nov 14, 20252 filingsAug 10, 2026SEC
SBSWSibanye Stillwater Ltd13G/A5.32%150.7M shares–May 15, 20261 filingMay 15, 2026SEC
MOHMolina Healthcare, Inc.13G5.21%2.72M sharesNewSep 3, 20261 filingSep 3, 2026SEC

Latest filings

6 filings on file made by Exor Capital LLP or listing it as a reporting person, newest first.

Schedule 13D and 13G filings by Exor Capital LLP
CompanyFiled (ET)FormStakeChangeEvent dateFiling
MOHMolina Healthcare, Inc.Sep 3, 20269:15 AM ET13G5.21%2.72M sharesNewAug 28, 2026SEC
VALValaris LtdAug 10, 20269:30 AM ET13G/A3.48%2.41M shares–Below 5%Jun 30, 2026SEC
VEONVEON Ltd.Aug 10, 20269:05 AM ET13G/A7.12%131.6M shares−1.62 ppfrom 8.74%Jun 30, 2026SEC
SBSWSibanye Stillwater LtdMay 15, 20269:13 AM ET13G/A5.32%150.7M shares–Mar 31, 2026SEC
VEONVEON Ltd.Nov 14, 202510:18 AM ET13G/A8.74%151.1M shares–Sep 30, 2025SEC
NGNovagold Resources IncAug 11, 202510:22 AM ET13G8.58%34.9M sharesNewJun 30, 2025SEC